IP Law 360

NOVEMBER 7, 2024

With a number of major reforms to the European Union's design protection system set to take effect in the first half of 2025, U.S. companies need to stay informed about specific details to maintain effective intellectual property management in the EU market, say lawyers at Finnegan.

Intellectual Property Management 52

Intellectual Property Management Design Designs Intellectual Property 52

LexBlog IP

MARCH 6, 2024

Under the agreement, Biocon can launch YESAFILI in Canada no later than July 1, 2025. The post Biocon Settles with Bayer and Regeneron, Securing Canada Market Entry Date for Aflibercept Biosimilar appeared first on Big Molecule Watch. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canada.

Marketing 52

Marketing Marketing Settlement Litigation 52

The IPKat

AUGUST 31, 2023

Open-Source: Requiring code to be openly available may promote transparency and innovation; allowing it to be proprietary may concentrate market power but allow more dependable regulation of harms. Existential: Some people think that AI is a major threat to human life. You can read the full report here.

Reporting 89

Reporting Technology Intellectual Property Government 89

The IPKat

AUGUST 13, 2024

Paid Internship at Ericson: Economist in the Intellectual Property Rights (IPR) Policy Research Team (m/f/d). Topics to be covered include: how will the EU IP Action Plan impact the Single Market? AlgoSoc International Conference 2025: 10 April 2025. 2025 Annual Meeting, 17 May 2025, San Diego, California, USA.

Intellectual Property 62

Intellectual Property IP Journalism Confidentiality 62

The IPKat

FEBRUARY 29, 2024

Role of EUIPO The role of European Union Intellectual Property Office (EUIPO) in examining the GI applications was one of the most contentious points in the negotiations over the GI Regulation. It will be applicable as of 1 January 2025. Examination at the EU-wide level will be conducted by the European Commission.

Art 109

Art Registration Journalism Intellectual Property 109

LexBlog IP

MARCH 6, 2024

The agreement allows Biocon to launch in the United States in February 2025, pending FDA approval. entry date for its ustekinumab biosimilar, WEZLANA, of January 1, 2025, and in October 2023, the FDA approved WEZLANA as biosimilar to and interchangeable with STELARA. Amgen secured a U.S.

Marketing 40

Marketing Marketing Settlement Licensing 40

Olartemoure Blog

MAY 24, 2024

In addition to what was previously reported, this new law includes a sanctioning regime for those producers or marketers who fail to comply with it, as follows: Fines between USD 85,055 to USD 102,066 for non-compliance with labeling obligations and warning seals on packaging.

Advertising 52

Advertising Advertising Intellectual Property Reporting 52

Indiana Intellectual Property Law

NOVEMBER 12, 2024

Novartis is a Swiss pharmaceutical company known for developing innovative medicines and therapies, particularly in the radiopharmaceutical market. The company is taking steps to strengthen its position by filing lawsuits against competitors over alleged patent violations concerning its top cancer therapies, Pluvicto and Lutathera.

Patent 52

Patent Marketing Marketing Design 52

LexBlog IP

DECEMBER 13, 2023

Samsung Bioepis recently reported that it has signed a settlement and license agreement with Johnson & Johnson (“J&J”) in the United States relating to SB17, Samsung Bioepis’s ustekinumab biosimilar to J&J’s STELARA® If SB17 is approved by the FDA, the license period in the United States will begin on February (..)

Litigation 52

Litigation Settlement Licensing Marketing 52

The IPKat

OCTOBER 7, 2024

CIPIL (University of Cambridge) Evening Seminars The Centre for Intellectual Property and Information Law (CIPIL) at the University of Cambridge has published its programme of evening seminars for the Michaelmas Term. They are: Will Indigenous Peoples’ Knowledge Transform Intellectual Property?

Intellectual Property 62

Intellectual Property Copyright Law IP Copyright 62

LexBlog IP

JUNE 13, 2023

. “According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025.” The post Alvotech and Teva Reach Ustekinumab (STELARA) Settlement with J&J appeared first on Big Molecule Watch.

Settlement 52

Settlement Marketing Marketing Licensing 52

SpicyIP

OCTOBER 27, 2024

Call for Papers: NLU Jodhpur’s Journal of Intellectual Property Studies Volume IX, Issue I [Submit by January 10, 2025] National Law University, Jodhpur’s Journal of Intellectual Property Studies is inviting original, unpublished manuscripts for its upcoming issue (Volume IX, Issue I).

Trademark 103

Trademark Copyright Cease and Desist Registration 103

The IPKat

OCTOBER 20, 2024

Unsurprisingly, the chapter on wine (Chapter 4) is the longest chapter, which includes additional detail about the regulations for wines in the Common Organisation of Agricultural Markets (CMO) in the new edition. Chapter 5 then considers the protection of spirits and the relevant case law.

Editing 73

Editing Law Intellectual Property Publishing 73

LexBlog IP

AUGUST 16, 2023

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.

Settlement 52

Settlement Licensing Confidentiality Marketing 52

Technology & Marketing Law Blog

FEBRUARY 29, 2024

Earlier this month, the High Tech Law Institute hosted the 2024 Works-in-Progress Intellectual Property ( WIPIP ), featuring nearly 90 presentations and over 110 attendees from four continents. WIPIP 2025 will be hosted by the UNLV Law School in Las Vegas. * * * As usual, Prof. The photo album. My memoriam for Dan.

Fair Use 69

Fair Use Intellectual Property IP Law 69

IIPRD

MARCH 17, 2023

Subsequently, the healthcare sector has gained precedence and command over the market. The global nutraceutical market (including functional food, functional beverages, and dietary supplements) is anticipated to grow by 7.5% (CAGR) between 2022 and 2027, in which the United State market share is considered to be the biggest.

IP 52

IP Intellectual Property Marketing Marketing 52

LexBlog IP

JANUARY 16, 2023

The European Commission expressed its hope that the provisions of the regulation will enter into force across all EU member states in 2025. These include, among others, the use to take decisions that may be detrimental to a natural person or the use for advertising or marketing.

Intellectual Property 52

Intellectual Property Confidentiality Business Advertising 52

LexBlog IP

JANUARY 12, 2023

Coherus plans to file an abbreviated Biologics License Application (aBLA) with the FDA later this year and intends to launch the product at EYLEA biosimilar market formation, currently expected to be in 2025.

Marketing 52

Marketing Marketing Licensing Intellectual Property 52

LexBlog IP

AUGUST 30, 2023

market on March 7, 2025, if approved by FDA. It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S.

Settlement 40

Settlement Confidentiality Marketing Marketing 40

The IPKat

NOVEMBER 9, 2023

Big) Kat in Tbilisi The Validation Agreement promises to bolster the protection of intellectual property rights within the industrial sector, thus safeguarding and promoting innovation and technological progress in the country. As of now, there are two traditional routes to obtain patent protection for an invention in Georgia.

Intellectual Property 67

Intellectual Property Patent Application Patent IP 67

IP Tech Blog

OCTOBER 31, 2023

Based on Ofcom guidance issued yesterday ( [link] ) it appears that the service provider categorisation process will not be completed until the end of next year at the earliest with draft proposals regarding the additional requirements for these larger providers to follow in early 2025.

Law 62

Law Social Media Publishing Technology 62

The IPKat

DECEMBER 20, 2024

Against this backdrop, larger issues emerge as regards the power wielded by AI companies in the medium to long term especially in a consolidated market, over social, economic and political aspects of our lives. The EU equivalents are contained in Articles 3 and 4 of Directive 2019/790 on Copyright in the Digital Single Market.

Copyright 62

Copyright Government Copyright Law Art 62

Intepat

OCTOBER 6, 2024

Patents , as a vital form of intellectual property (IP), safeguard these innovations, providing inventors and businesses exclusive rights to their inventions while promoting the dissemination of knowledge. In 2024, the PCT system is seeing increased usage as companies seek to protect their innovations in a broader range of markets.

Patent 52

Patent Intellectual Property Inventor Technology 52

LexBlog IP

OCTOBER 31, 2023

Based on Ofcom guidance issued yesterday ( [link] ) it appears that the service provider categorisation process will not be completed until the end of next year at the earliest with draft proposals regarding the additional requirements for these larger providers to follow in early 2025.

Law 52

Law Social Media Publishing Intellectual Property 52

LexBlog IP

JANUARY 11, 2022

Subscription marketing is on the rise with some predicting the subscription industry will more than double by 2025. Experts do not forecast this growth will taper off, as it is part of a larger trend of relationship-based marketing. Or perhaps the goal was really to drive app download and loyalty signups.

Marketing 52

Marketing Marketing Contracts Law 52

LexBlog IP

SEPTEMBER 28, 2023

to commercialize several of Abbott’s oncology, women’s health, and respiratory disease biosimilars for emerging markets in Latin America, Southeast Asia, the Middle East, and Africa. According to the press release, the first molecules subject to the agreement are expected to launch as early as 2025.

Marketing 40

Marketing Marketing Contracts Registration 40

IP and Legal Filings

NOVEMBER 15, 2024

have created a niche market in the gaming Industry, introducing special products for gaming. billion and is projected to reach USD 5 billion in 2025, according to a 2021 BCG report. Intellectual Property Acts Acts like the Copyright Act,1957, The Trademark Act, 1999, Patents Act, 1970, etc.

Advertising 97

Advertising Advertising Law Due Diligence 97

LexBlog IP

DECEMBER 2, 2021

The incorporation of drones in logistics, security, exploration, agriculture, and transport has led to a projected growth of the drone market to $129.2 billion by 2025.

Privacy 40

Privacy Marketing Marketing Law 40

Biswajit Sarkar Copyright Blog

DECEMBER 19, 2023

As India aims for a $5 trillion economy, the MSME ministry sets ambitious goals, aiming to elevate their GDP contribution by up to 50% by 2025. MSMEs foster innovation by nurturing aspiring entrepreneurs, encouraging the development of innovative goods that enhance market competitiveness and fuel sustained growth.

Settlement 52

Settlement Intellectual Property Registration Design 52

LexBlog IP

NOVEMBER 5, 2023

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.”

Marketing 40

Marketing Marketing Government Litigation 40

LexBlog IP

JUNE 29, 2023

To demonstrate irreparable harm, Biogen pointed to harm in the form of (1) price erosion, (2) lost sales and market share, and (3) reputational harm. For similar reasons, the Court found Biogen’s arguments about loss of market share too speculative. The Court also noted that any harm could be remedied by money damages.

Litigation 52

Litigation Marketing Marketing Patent 52

SpicyIP

DECEMBER 2, 2024

The plaintiff through its market survey allegedly found that the defendant was engaged in the business of storing/selling/marketing/distributing products under the falsified trademarks NIKE and Swoosh logo.

Invention 52

Invention Trademark Reporting Editing 52

LexBlog IP

FEBRUARY 1, 2024

In October 2023, Accord settled with Janssen Biotech under confidential terms that would allow Accord to launch its proposed ustekinumab biosimilar no later than May 15, 2025, pending FDA approval.

Confidentiality 40

Confidentiality Reporting Licensing Marketing 40

LexBlog IP

JANUARY 17, 2024

Any reporting company that is created or registered before January 1, 2024, must file a BOI report no later than January 1, 2025. The CTA takes effect on January 1, 2024.

Reporting 52

Reporting Business Editing Ownership 52

LexBlog IP

JANUARY 25, 2024

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.”

Marketing 40

Marketing Marketing Licensing Litigation 40

LexBlog IP

APRIL 25, 2023

” Government should announce a clear policy position on the relationship between intellectual property law and generative AI to provide confidence to innovators and investors. labelling) on generated output to support right holders of copyrighted work. and] will explore how this could be expanded.

Technology 52

Technology Government Reporting Intellectual Property 52

LexBlog IP

AUGUST 29, 2023

Any reporting company that is created or registered before January 1, 2024, must file a report no later than January 1, 2025. Reports will not be accepted prior to January 1, 2024. FinCEN is currently in the process of creating the specific reporting system and additional regulations surrounding the CTA.

Reporting 52

Reporting Ownership Business Editing 52